曼恩凯德制药

US · MNKD #3124 按市值排名上市于 2016

3.04 -0.15 -4.70%

实时 - 追踪5344个代码 - 心跳于523秒前 · 2026-10-16 19:53

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了1家。
机构持股总比例下降了2.7个百分点。

机构持股

机构持股比例: 57.55% -2.75pp
机构数量: 308 +1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund36.72%

Hedge Fund10.62%

VC/PE Fund3.93%

Public Company3.30%

Individual/Insider1.85%

Family Office/Trust1.61%

Private Company0.65%

Government Pension Fund0.48%

Insurance Company0.20%

Other40.64%

主要股东截至 2026-06-30

BlackRock 9.99% · 32.13M 股

Rubric Capital Management LP 5.60% · 18.00M 股

State Street Global Advisors 5.03% · 16.17M 股

Vanguard Capital Management, LLC 4.78% · 15.37M 股

Geode Capital Management, LLC 2.47% · 7.95M 股

Wellington Management Group 2.44% · 7.84M 股

Frazier Life Sciences Management, LP 2.05% · 6.60M 股

Deep Track Capital, LP 1.87% · 6.00M 股

180 Wealth Advisors, LLC 1.54% · 4.96M 股

FMR 1.28% · 4.10M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 29次买入 · 21次卖出

姓名	职务	持股比例
Michael Castagna	Chief Executive Officer	0.76%
Stuart Tross	Executive VP and Chief People & Workplace Officer	0.27%
David Thomson	General Counsel	0.19%
Steven Binder	Chief Financial Officer	0.17%
Burkhard Blank	Executive VP of Research & Development and Chief Medical Officer	0.08%
Sanjay Singh	Executive Vice President of Technical Operations	0.08%
Anthony Hooper	Independent Director	0.07%
Lauren Sabella	Chief Operating Officer	0.04%
Ronald Consiglio	Independent Director	0.04%
Jennifer Grancio	Independent Director	0.03%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-24	Steven Binder	Chief Financial Officer	Automatic Disposition	-39,051	$3.29
2026-09-09	Steven Binder	Chief Financial Officer	Automatic Disposition	-33,558	$3.81
2026-08-06	Steven Binder	Chief Financial Officer	Automatic Disposition	-39,051	$4.06
2026-07-16	David Thomson	General Counsel	Automatic Disposition	-24,109	$4.05
2026-07-16	Steven Binder	Chief Financial Officer	Derivative Exercise and Sale	-76,880	$4.06–4.09
2026-07-14	David Thomson	General Counsel	Sale to Issuer	-4,636	$4.09
2026-07-14	David Thomson	General Counsel	Derivative Exercise and Sale	-93,790	$4.09
2026-07-14	Stuart Tross	Executive VP and Chief People & Workplace Officer	Derivative Exercise and Sale	-65,808	$4.09
2026-07-14	Stuart Tross	Executive VP and Chief People & Workplace Officer	Derivative Exercise and Retained	+27,982	--
2026-07-14	Michael Castagna	Chief Executive Officer	Sale to Issuer	-12,940	$4.09
2026-07-14	Michael Castagna	Chief Executive Officer	Derivative Exercise and Sale	-350,260	$4.09
2026-07-14	Steven Binder	Chief Financial Officer	Derivative Exercise and Retained	+16,910	--
2026-07-14	Christopher Prentiss	Chief Financial Officer	Sale to Issuer	-22,247	$4.09
2026-07-14	Dominic Marasco	President of Endocrine Business Unit	Sale to Issuer	-3,623	$4.09
2026-07-14	Sanjay Singh	Executive Vice President of Technical Operations	Derivative Exercise and Sale	-46,795	$4.09
2026-07-14	Sanjay Singh	Executive Vice President of Technical Operations	Derivative Exercise and Retained	+23,755	--
2026-05-19	Ronald Consiglio	Independent Director	Other Acquisition	+10,000	$2.95
2026-05-19	Ronald Consiglio	Independent Director	Other Derivative Acquisition	+99,337	--
2026-05-19	Christine Ann Mundkur	Independent Director	Other Derivative Acquisition	+82,781	--
2026-05-19	Michael Friedman	Independent Director	Other Derivative Acquisition	+82,781	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:53:46 · 仅供参考，不构成投资建议，也未考虑您的具体情况。